Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PTPRC | P08575 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29492487 | 1.00 | ALDH1A1 (0.54) | ALDH1A1HSD17B10MAPTPOLBMAPK1 | |
| SCHEMBL1027801 | 0.83 | ALDH1A1 (0.54) | ALDH1A1HSD17B10MAPTPOLBMAPK1 | |
| SCHEMBL5523993 | 0.83 | ALDH1A1 (0.50) | ALDH1A1HSD17B10MAPTPOLBMAPK1 | |
| SCHEMBL29573133 | 0.81 | GPR35 (0.53) | ALDH1A1MAPTPOLBMAPK1IDO1 | |
| SCHEMBL11518803 | 0.81 | GPR35 (0.53) | ALDH1A1MAPTPOLBMAPK1IDO1 | |
| SCHEMBL30006434 | 0.79 | MAPK1 (0.52) | ALDH1A1MAPTMAPK1PTGDR2KDM4E | |
| SCHEMBL364027 | 0.79 | MAPK1 (0.52) | ALDH1A1MAPTMAPK1PTGDR2KDM4E | |
| SCHEMBL19190198 | 0.79 | PTPRC (0.56) | ALDH1A1MAPTMAPK1PTGDR2KDM4E | |
| SCHEMBL1321489 | 0.79 | ALDH1A1 (0.61) | ALDH1A1HSD17B10MAPTKDM4EMEN1 | |
| SCHEMBL5214073 | 0.79 | IDO1 (0.42) | ALDH1A1MAPTIDO1GPR35KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024109919-A1 | PYRIDONE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 盛睿泽华医药科技（苏州）有限公司 | 2024-05-30 | — | — | WO | disclosed |
| US-20230174485-A1 | LIPOXYGENASE INHIBITORS | SRI INTERNATIONAL (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174485-A1 | LIPOXYGENASE INHIBITORS | SRI INTERNATIONAL (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174485-A1 | LIPOXYGENASE INHIBITORS | SRI INTERNATIONAL (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230117592-A1 | LIPOXYGENASE INHIBITORS | SRI INTERNATIONAL (US) | 2023-04-20 | — | — | US | disclosed |
| EP-4125874-A1 | LIPOXYGENASE INHIBITORS | SRI International (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115335046-A | Lipoxygenase inhibitors | 思研（SRI）国际顾问与咨询公司 | 2022-11-11 | — | — | CN | disclosed |
| EP-4081199-A2 | LIPOXYGENASE INHIBITORS | SRI International (US) | 2022-11-02 | — | — | EP | disclosed |
| CN-115135316-A | Lipoxygenase inhibitors | 思研（SRI）国际顾问与咨询公司 | 2022-09-30 | — | — | CN | disclosed |
| CN-112898352-B | Asymmetric palladium complex, preparation method and application thereof in catalyzing olefin polymerization | 中山大学 | 2022-03-22 | — | — | CN | disclosed |
| EP-1664065-A1 | SILICON COMPOUNDS WITH MICROBIOCIDAL ACTIVITY | Syngenta Participations AG (CH) | 2006-06-07 | — | — | EP | disclosed |
| EP-1114052-B1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | ABBOTT GMBH & CO KG (DE) | 2005-11-16 | — | — | EP | disclosed |
| WO-2005028485-A1 | SILICON COMPOUNDS WITH MICROBIOCIDAL ACTIVITY | SYNGENTA PARTICIPATIONS AG (CH) | 2005-03-31 | — | — | WO | disclosed |
| US-20030187001-A1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-10-02 | — | — | US | disclosed |
| CN-1326457-A | 4-aminopyrrolopyrimidines as kinase inhibitors | BASF AG (DE) | 2001-12-12 | — | — | CN | disclosed |
| EP-1114052-A1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000017202-A1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-30 | — | — | WO | disclosed |
| US-4670566-A | ANTIIFLAMMATORY AGENTS, ANTICOAGULANTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1987-06-02 | — | — | US | disclosed |
| US-4647560-A | COGNITION ACTIVATORS | TROPONWERKE GMBH & CO. KG (DE) | 1987-03-03 | — | — | US | disclosed |
| US-4440785-A | Methods of using 2-aminobiphenylacetic acids, esters, and metal salts thereof to treat inflammation | A. H. ROBINS COMPANY, INC. (US) | 1984-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117592-A1 | LIPOXYGENASE INHIBITORS | ALOX15B, ALOX12, ALOX5 | ALDH1A1 203/4885HSD17B10 188/4885MAPT 2110/4885 |
| US-20230174485-A1 | LIPOXYGENASE INHIBITORS | ALOX15B, ALOX12, ALOX15 | ALDH1A1 133/4885HSD17B10 161/4885MAPT 1601/4885 |
| US-20030187001-A1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | LCK, PPP5C, DUSP1 | ALDH1A1 1059/4885HSD17B10 3275/4885MAPT 2881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.